CV3: UTILIZATION OF ACE INHIBITORS IN CONGESTIVE HEART FAILURE AMONG THE ELDERLY IN QUEBEC  by LeLorier, J et al.
Abstracts 13
garding the potential effects of treating all patients with
hypercholesteremia age 45 to 65.
METHODS: The current analysis is based on a model
that approximates the discounted lifetime costs of all
patients who presented themselves in 1996 to a German
hospital for either primary or secondary events of coro-
nary heart disease. The costs of this cohort in 1996 and
up to their projected end of life were estimated, including
all direct and indirect costs. Data for direct costs were
generated from the federal bureau of statistics, sickness
funds, retirement funds, hospital admission data sources,
primary care panel physician data, and other sources. In
calculating indirect costs, gender- and age-specific unem-
ployment rates were considered. Additionally, the effects
on revenues and expenses for sickness funds and other
parts of the social security system were estimated. Thus,
the model allows cost-effectiveness studies from the per-
spective of society as well as from the perspective of the
social security system and parts of it, including the effects
on retirement payments.
RESULTS: Direct costs are approximately 31 billion US$
discounted at 4%. Indirect costs total 40 billion US$ dis-
counted at 4%. The model was used to calculate the cost-
effectiveness of treating all patients for secondary preven-
tion and all patients with a total cholesterol of 250 mg/dl
irrespective of further risk factors in the age group 45–65
from the perspective the social security system and the
perspective of society. For this age group, there is little
difference between these two perspectives and a com-
bined cost-effectiveness of 33,000 US$ per life-year saved.
The results are highly sensitive for the price of the pre-
scribed statins. 
CONCLUSION: Primary and secondary prevention can
be cost-effective in the age group 45–65 for both genders,
from both the perspective of society as well as the social
security system.
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BACKGROUND: In 1991, SOLVD demonstrated a de-
crease in hospitalization and mortality rates by using an-
giotensin-converting enzyme inhibitors (ACEI) in chronic
congestive heart failure (CHF).
METHODS: We conducted a study on a 10% random
sample of subjects aged 65 years and older from the uni-
versal health insurance plan in Quebec. We studied all the
elderly who had a dispensation of digoxin (0.125 mg/d)
and furosemide (40 mg/d) (DF) from September 1991 to
December 1994.
RESULTS: Among 3,565 subjects, 61.7% used an ACEI at
least once after the first dispensation of DF. Visiting a car-
diologist was the strongest predictor of an ACEI dispensa-
tion (OR 1.58; 95% CI 1.44–1.74). The use of ACEI re-
mained stable from 1991 to 1994 (p  0.92). In a
subgroup of subjects free of ACEI and of any combination
of digoxin/furosemide 1 year prior to the first DF dispen-
sation (incident cases), 51.7% had at least one dispensa-
tion of an ACEI following the first dispensation of DF.
Among these incident users of DF, 79.3% began the ACEI
in the 3 months following the first dispensation of DF.
CONCLUSION: In the elderly taking digoxin and furo-
semide, the use of ACEI is widespread. Since the publica-
tion of SOLVD in 1991, there has been no change in the
utilization of ACEI over time.
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OBJECTIVES: We have recently shown that continuous
coronary perfusion with warm blood enriched with the
ultra–short acting -blocker Esmolol (ES) improves func-
tional and structural myocardial protection during coro-
nary artery bypass grafting (CABG) as compared with
conventional cardioplegia (CP). The purpose of the present
study was to compare the myocardial protection tech-
niques in terms of patient outcome and economical as-
pects.
METHODS: We retrospectively analyzed the charts of
150 consecutive patients who received CABG using the
ES technique; 150 patients matched for age, gender, pre-
operative left ventricular function, history of renal fail-
ure, and history of neurological symptoms who under-
went CABG using the conventional CP-technique served
as the control group.
RESULTS: There were no significant differences between
the groups with respect to perioperative myocardial in-
farction rate, need for positive inotropic medication, need
for mechanical circulatory support, duration of mechani-
cal ventilation, duration of intensive care unit stay, time
of mobilization, postoperative renal failure, cardiac ar-
rhythmias, neurological symptoms, infections or in-hospi-
tal mortality. However, ES patients were less frequently
re-admitted to the intensive care unit (ES: 3 of 150 [2%]
vs. CP: 13 of 150 [9%]; p  0.015) and discharged ear-
lier from the hospital (ES: 12.3  4.8 days vs. CP: 13.5 
3.8 days; p  0.009). In addition, the ES technique itself
was more economical (drug costs for ES technique: about
DM 120 per patient vs. CP technique: about DM 260 per
patient). 
CONCLUSIONS: Our data suggest that improved myo-
cardial protection during CABG using the ES technique
may be a cost-saving alternative to the conventional CP
technique due to both shorter hospital stay and lower
procedural costs.
